Is the plasma endocan level a reliable predictor for the severity of erectile dysfunction?

The aim of our study was to assess the correlation between serum endocan level and erectile dysfunction (ED).

A total of 92 patients were reviewed in this study after institutional review board approval. The patients’ characteristics were recorded, including age, body mass index, blood pressure, smoking history, serum creatinine, glucose, lipid profile, total testosterone, and Beck Depression Inventory scores. ED was evaluated with the Sexual Health Inventory for Men (SHIM) questionnaire and classified as severe, moderate, or mild. Scores of > 18 indicate normal erectile function and were recruited for the control group.

Sixty-three patients with a median age of 56 years in the ED group and 29 patients with a median age of 55 years in the control group were compared. ED was classified as severe in 20, moderate in 25, and mild in 18 patients. A significant difference was determined between the severe ED group and the control group for serum endocan levels (p < 0.001). A significant negative correlation between the SHIM score and endocan levels (rho − 0.65; p < 0.01), age and SHIM score (rho − 0.32; p = 0.04), BMI and SHIM score (rho − 0.25; p = 0.03), and BMI and total testosterone (rho − 0.16; p = 0.04) was determined upon Spearman’s correlation analysis. A positive correlation was also determined between total testosterone and SHIM score (rho 0.50; p = 0.04). Patients’ age (p = 0.037) and serum endocan level (p = 0.029) were determined as significant in the multivariate analysis.

This study demonstrated the presence of an association between plasma endocan levels and ED. Endocan may be used as a new diagnostic marker for the severity of ED.